Gastroenterologie
a hepatologie

Evaluation and applicability of nonbiopsy criteria in children and adolescents according to ESPGHAN for diagnosis of celiac disease

Jarmila Kabátová^1,2, Rastislav Husťak^3,4,5, Stanislava Blažíčková ^{Orcid.org  2}, Vladimír Bošák ^{Orcid.org  6}

+ Affiliation
¹ Gastroenterologická ambulancia, Odborná detská ambulancia, s.r.o., Piešťany
² Katedra laboratórnych vyšetrovacích metód v zdravotníctve, FZaSPTU v Trnave, Slovenská republika
³ Gastroenterologická a endoskopická ambulancia, Interná klinika FZaSP TU a FN Trnava
⁴ Katedra laboratórnych vyšetrovacích metód v zdravotníctve, FZaSPTU v Trnave
⁵ 1. LF UK v Praze
⁶ Katedra laboratórnych vyšetrovacích metód v zdravotníctve, FZaSP TU v Trnave, Slovenská republika

Summary

The paper focuses on the analysis of anti-tissue transglutaminase 2 (anti-TG2) antibodies and endomysial antibodies (EMA) and HLA-DQ2/HLA-DQ8 haplotypes present in symptomatic children and adolescents with suspected coeliac disease. This refers to applying the new 2012 ESPGHAN criteria allowing to make the diagnosis of coeliac disease without an enterobiopsy. A total of 258 children and adolescents (86 males and 172 females), aged 2–18 years, were retrospectively examined to determine the performance of coeliac disease testing according to national guidelines from 2009. The obtained data were applied according to the revised 2012 ESPGHAN criteria allowing to make the diagnosis of coeliac disease in indicated cases without an anterobiopsy. The nonbiopsy criteria revealed that 33.3% (86) of symptomatic children and adolescents in our cohort with high anti-TG2 titers and positive EMA could have been initially diagnosed without an intestinal biopsy. All patients presented with advanced intestinal atrophy Marsh 2–3. Part of the rationale of the study was to determine the sensitivity and specificity, the positive and negative predictive values of the final laboratory tests, and the diagnostic accuracy of the combined tests using antibodies.

Keywords

EMA, ESPGHAN, HLA-DQ2/HLA-DQ8, anti-TG2, coeliac disease

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Husby S, Koletzko S, Korponay-Szabó et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54 (1): 136–160. doi: 10.1097/ MPG.0b013 e31821a23d0.
2. Pekárková B, Pekárek B, Kabátová J. Štandardný diagnostický a terapeutický postup. 46. metodický list racionálnej farmakoterapie. Racionálna diagnostika a liečba celiakie 2009; 13 (1–2):  1–7.
3. Nevoral J, Kotalová R, Hradský O et al. Symptom positivity is essential for omit-ting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines. Eur J Pediatr 2014; 173 (4): 497–502. doi: 10.1007/s00431-013-2215-0.
4. Frühauf P, Bronský J, Dědek P et al.  Celiakie – doporučený postup pro diagnostiku a terapii u dětí a dospívajících. Čes-slov Pediat 2016; 71 (3):  175–183.
5. Kubina M, Čierna I, Székyová D et al. Niektoré genetické determinanty celiakie, význam HLA typizácie v klinickej praxi a zastúpenie HLA-DQ haplotypov v súbore 306 detských pacientov. Gastroent Hepatol 2016; 70 (6): 475–479. doi: 10.14735/amgh2016475.
6. Smarrazzo A, Misak Z, Costa S et al. Diag-nosis of celiac disease and applicability of ESPGHAN guidelines in Mediterranean countries: ad real life prospective study. BMC Gastroenterol 2017; 17 (1): 17. doi: 10.1186/s12876-017-0577-x.
7. Gidrewicz D, Potter K, Trevenen CL et al. Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population. Am J Gastroenterol 2015; 110 (5): 760–767. doi: 10.1038/ajg. 2015.87.
8. International Organization for Standardization. ISO 15189: 2012 Medical laboratiories – Requirements for quality and competence. [online]. Availabe from: www.iso.org/standard/56115.html.